Skip to content

Effectiveness of complementary integrative therapy with fasting in patients with diabetes mellitus type 2 and metabolic syndrome: A randomized controlled pilot study.

Effectiveness of complementary integrative therapy with fasting in patients with diabetes mellitus type 2 and metabolic syndrome: A randomized controlled pilot study.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00004715
Enrollment
40
Registered
2013-06-03
Start date
2013-01-30
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E11.90 E88.9

Interventions

Group 1: Subjects from group 1 receive outpatient complementary integrative therapy with nutrition therapy (fasting for 7 days) and mind body medicine for 12 weeks. At the beginning the subjects star

Sponsors

Abteilung für Naturheilkunde der Charité im Immanuel-Krankenhaus Berlin-Wannsee
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. A signed consent form 2. Age 25 - 70 years 3. Existence of a specialist secure type 2 diabetes mellitus (HbA1c> 7%) 4. Maximum basal insulin 40 IU 5. BMI > 25Kg/cm ² 6. Waist cm men > 94, women > 80 cm 7. Patient is intellectually and linguistically able to understand the significance of the study

Exclusion criteria

Exclusion criteria: 1. Pregnancy, lactation period 2. Diabetes mellitus type-1 with basal-bolus insulin therapy 3. Lack of insulin C-peptide> 1.2 ng / dl 4. Hypotension 2b 10. Diabetic foot syndrome > Wagner 1, A Armstrong 11. Manifest eating disorder or binge-eating disorder 12. Serious acute somatic disease or infectious disease 13. Severe or acute mental illness 14. Simultaneous participation in another study

Design outcomes

Primary

MeasureTime frame
Change in long-term blood sugar (HbA1c) using a blood collection: baseline (day 0) versus endpoint (12 weeks).

Secondary

MeasureTime frame
- HOMA score for insulin sensitivity - Quality of Life (WHO-5) - Overall assessment of efficacy and tolerability (Likert scale) by the patient - Weight, abdominal girth - HbA1 C, glucose and insulin levels - Blood pressure, systolic / diastolic - Blood lipids (Chol LDL-C, HDL-C, TG): baseline (day 0) versus endpoint (12 weeks).

Countries

Germany

Contacts

Public ContactBadri Sadraie

diR Schwerpunktpraxis Diabetes & Rheuma Wilmersdorf

Konakt@dir-praxis.de0049(0)308243368

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026